Olean Times Herald

HONG KONG , April 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD...

HONG KONG , April 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Adminis...

HONG KONG , April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigationa...

Key Highlights: HONG KONG , March 30, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing ...

HONG KONG , March 28, 2025 /PRNewswire/ --Akeso Inc. (9926.HK) ("the Company") will hold a conference call to discuss its full-year 2024 results on Mo...

HONG KONG , March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 s...

HONG KONG , March 16, 2025 /PRNewswire/ --Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab...

HONG KONG , March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of t...

HONG KONG , March 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollmen...